Back to search

Switzerland· 53349001

Rinosedin 0,05 %, Nasentropfen, Lösung

A xylometazoline product, registered in Switzerland by Streuli Pharma AG and dispensed under Swissmedic category D. The same ATC class is registered in 14 of our 19 countries.

Cat D (Swissmedic)ATC R01AA07

Checked against the register on

Informational only — not a medical device.

SOURCE REGISTER · CHPublic registernormalisedRinosedin 0,05 %, Nasentropfen, LösungATCR01AA07REGISTER NO.53349001PACKS LISTED0CHECKEDJune 26, 2026

Where it is registered

Xylometazoline is registered in 14 of 19 countries.

Countries holding a registration under ATC R01AA07 (xylometazoline), each read from that country’s own register.

  • This record: Switzerland
  • 8 of them publish a price we can compare per daily dose

Xylometazoline · ATC R01AA07

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Manufacturer
Streuli Pharma AG
Country
Switzerland (CH)
ATC code
R01AA07
ATC class
Xylometazoline
Defined daily dose
0.8 mg, N
Swissmedic category
D
Reimbursed
No
Last checked
June 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

63 interactions on record for xylometazoline.

Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Xylometazoline · interactions on record

63 records

  • 6 severe
  • 54 moderate

Most severe, free to view

  • MethylergometrineG02AB01severe
  • DihydroergotamineN02CA01severe
  • ErgotamineN02CA02severe
  • MethysergideN02CA04severe

3 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ec2b5891-2daa-4164-af91-4b4f62360bb6
GET /v1/drugs/ec2b5891-2daa-4164-af91-4b4f62360bb6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "source": "swissmedic_auth",
  "heilmittelcode": "Synthetika"
}

See everything about xylometazoline.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.